Aptevo Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, except share amounts)
| Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders' | |||||||
| Shares · Amount · Capital · Deficit · Equity | |||||||
| Balance at December 31, 2022 | 3,971 | $48 | $223,962 | $(206,036) | $17,974 | ||
| Common stock issued upon vesting of restricted stock units and exercised stock options | 59 | — | (10) | — | (10) | ||
| Issuance of common stock | 5,587 | 9 | 6,419 | — | 6,428 | ||
| Warrant inducement, net of issuance cost (1) | 2,341 | 4 | 963 | — | 967 | ||
| Warrant modification - incremental fair value | — | — | 2,080 | — | 2,080 | ||
| Stock-based compensation | — | — | 2,193 | — | 2,193 | ||
| Net loss for the period | — | — | — | (17,411) | (17,411) | ||
| Balance at December 31, 2023 | 11,958 | $61 | $235,607 | $(223,447) | $12,221 | ||
| Common stock issued upon vesting of restricted stock units and exercised stock options | 94 | (1) | (1) | ||||
| Payment in lieu of fractional shares (2) | (46) | — | (3) | — | (3) | ||
| Issuance of common stock, net of issuance cost (3) | 622,893 | 22 | 9,542 | — | 9,564 | ||
| Warrant inducement, net of issuance cost | 823,544 | 1 | 5,562 | — | 5,563 | ||
| Warrant modification - incremental fair value (3) | — | — | 472 | — | 472 | ||
| Stock-based compensation | — | — | 1,069 | — | 1,069 | ||
| Net loss for the period | — | — | — | (24,130) | (24,130) | ||
| Balance at December 31, 2024 | 1,458,443 | $84 | $252,248 | $(247,577) | $4,755 | ||
(1) Includes gross proceeds of $3.3 million less issuance costs of $2.3 million, which includes $2.1 million warrant modification incremental fair value.
(2) Payments were made in lieu of fractional shares in connection with the 1-for-44 and 1-for-37 reverse stock splits effected on March 5 and December 3, 2024, respectively.
(3) Includes gross proceeds of $11.5 million less issuance costs of $1.9 million, which includes $0.5 million warrant modification incremental fair value.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.